학술논문
Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24Month Results of a Phase 2 Study
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15280020